Items where authors include "Cook, AD"

Article

Blagden, SP, Cook, AD, Poole, C et al. (16 more authors) (2020) Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. The Lancet Oncology, 21 (7). pp. 969-977. ISSN 1470-2045

Colomban, O, Tod, M, Peron, J et al. (6 more authors) (2020) Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). JNCI Cancer Spectrum, 4 (3). pkaa026. pkaa026-. ISSN 1475-4029

Clamp, AR, James, EC, McNeish, IA et al. (26 more authors) (2019) Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. The Lancet, 394 (10214). pp. 2084-2095. ISSN 0140-6736

Conaghan, PG orcid.org/0000-0002-3478-5665, Cook, AD, Hamilton, JA et al. (1 more author) (2019) Therapeutic options for targeting inflammatory osteoarthritis pain. Nature Reviews Rheumatology, 15. pp. 355-363. ISSN 1759-4790

Oza, AM, Cook, AD, Pfisterer, J et al. (21 more authors) (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncology, 16 (8). pp. 928-936. ISSN 1470-2045